Tenderwize
Zurück zur Suche

Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2027 · 429 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab

5/100

Opportunity Score

High riskLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

5 / 100

Komplexität

30 / 100

Risikofaktoren

The XML change notice states the procedure was prematurely ended on 30.06.2026. The structured data still shows a futur...

No estimated contract value or framework maximum is provided. The financial attractiveness cannot be assessed.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Weak opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Conclusion of drug discount agreements for the active substance Omalizumab under German social law (§130a Abs. 8 SGB V).
  • Open House procedure: no individual negotiations, uniform conditions, no exclusivity.
Vollständige Zusammenfassung anzeigen

This notice concerns an Open-House procedure (not a classic EU procurement) for discount agreements on the active substance Omalizumab, under §130a Abs. 8 SGB V. The lead buyer is Techniker Krankenkasse. The procedure was originally open until October 2027, but a change notice (XML) indicates the procedure was prematurely ended on 30 June 2026. No estimated value is provided. Only one lot exists. Eligibility requires pharmaceutical entrepreneur status with proper authorization. Award criteria are not specified (placeholder only). Documents were not analyzed. Due to the premature termination, this tender is effectively closed.

Risiken

The XML change notice states the procedure was prematurely ended on 30.06.2026. The structured data still shows a futur...

No estimated contract value or framework maximum is provided. The financial attractiveness cannot be assessed.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with a valid authorization for the offered medicinal product.
  • Sitz in Germany, another EU member state, or EEA state (§9 Abs. 2 Satz 1 AMG).

Eligibility

  • Declaration of eligibility and reliability (Anlage 4) to be signed in text form.

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No explicit award criteria; procedure is Open House with uniform conditions, not a competitive award.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab

Conclusion of discount agreements for Omalizumab with all eligible pharmaceutical entrepreneurs. No exclusivity, fixed conditions. Max contract duration 24 months from 01.11.2025 to 31.10.2027.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Oct 2025 - Oct 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No explicit award criteria; procedure is Open House with uniform conditions, not a competitive award.

Frist

Deadline Oct 30, 2027

Vergabedetails

Veröffentlichungsdatum
20 May 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
347743-2026

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3